BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 20 August 1997.
- Saliva Diagnostic Systems to begin aggressive sales campaign for Saliva-Strip(TM) HIV -
A rapid test that uses saliva to detect HIV antibodies will be marketed for professional use in the United Kingdom, medical diagnostics maker Saliva Diagnostic Systems, Inc. (Nasdaq: SALV) reported today. Saliva-Strip(TM) HIV recently received a certificate of free sale from the Department of Health there, allowing the test to be distributed for professional use within the UK and exported from there to other countries. The company intends to begin an aggressive sales campaign to introduce the rapid test to hospitals and clinicians throughout Great Britain, said Chief Executive Officer Kenneth McLachlan.
"We have also recently received a similar certificate for Hema-Strip(TM) HIV, a rapid whole blood test that detects HIV antibodies, and plan to market both products in the UK as reliable screening devices for HIV infection," said McLachlan. Both tests provide results in minutes without the use of special equipment, training or storage. Saliva-Strip, which is completely non-invasive, has a sensitivity and specificity of 99.4 percent. Hema-Strip, which uses a small drop of whole blood from a finger stick, has a sensitivity and specificity of 99.8 percent and 100 percent, respectively.
The company also plans to submit Stat-Simple(TM) pylori, a rapid whole blood test to detect Helicobacter pylori (a bacterium believed to cause peptic ulcers and gastric cancers) in the United Kingdom. Hema-Strip HIV has been approved for use and sale in Russia, while another rapid test, Sero-Strip(TM) HIV, has been approved in Russia, Brazil and India. The company plans to apply to other countries for regulatory approval to distribute its rapid test products.
Saliva Diagnostic Systems is a developer and manufacturer of medical specimen collectors and rapid tests for infectious diseases and certain other conditions, based in Vancouver, Washington with operations in Singapore and London. The company is currently developing rapid tests for Hepatitis A and Tuberculosis.
This press release contains forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially include the following: changes in demand for the company's products, the ability of the company to increase manufacturing capacity, the ability of the company to obtain regulatory approvals, success in technological advances and their implementation, cost and yield issues associated with production, the ability of the company to raise additional capital, and other risk factors listed in the company's Amendment No. 1 to the Registration Statement dated June 13, 1997.
--30--CER/se*
CONTACT: Saliva Diagnostic Systems, Inc. Joni O'Donahue, 360/696-4800
Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970820
BW970815
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .